These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 34360966)

  • 1. Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases.
    Trudler D; Ghatak S; Lipton SA
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening.
    Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem Cell Therapies in Alzheimer's Disease: Applications for Disease Modeling.
    Si Z; Wang X
    J Pharmacol Exp Ther; 2021 May; 377(2):207-217. PubMed ID: 33558427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis.
    Lee JH; Liu JW; Lin SZ; Harn HJ; Chiou TW
    Cell Transplant; 2018 Sep; 27(9):1301-1312. PubMed ID: 30033758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.
    Cao L; Tan L; Jiang T; Zhu XC; Yu JT
    Mol Neurobiol; 2015 Aug; 52(1):244-55. PubMed ID: 25146848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling.
    Centeno EGZ; Cimarosti H; Bithell A
    Mol Neurodegener; 2018 May; 13(1):27. PubMed ID: 29788997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders.
    Okano H; Morimoto S
    Cell Stem Cell; 2022 Feb; 29(2):189-208. PubMed ID: 35120619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease.
    Campos HC; da Rocha MD; Viegas FP; Nicastro PC; Fossaluzza PC; Fraga CA; Barreiro EJ; Viegas C
    CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):239-50. PubMed ID: 20874702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concise Review: Modeling Neurodegenerative Diseases with Human Pluripotent Stem Cell-Derived Microglia.
    Haenseler W; Rajendran L
    Stem Cells; 2019 Jun; 37(6):724-730. PubMed ID: 30801863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural stem cell-based treatment for neurodegenerative diseases.
    Kim SU; Lee HJ; Kim YB
    Neuropathology; 2013 Oct; 33(5):491-504. PubMed ID: 23384285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.
    Haggarty SJ; Silva MC; Cross A; Brandon NJ; Perlis RH
    Mol Cell Neurosci; 2016 Jun; 73():104-15. PubMed ID: 26826498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy.
    Dai S; Qiu L; Veeraraghavan VP; Sheu CL; Mony U
    Curr Stem Cell Res Ther; 2024; 19(6):809-819. PubMed ID: 37291782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease.
    Inak G; Lorenz C; Lisowski P; Zink A; Mlody B; Prigione A
    Stem Cells; 2017 Jul; 35(7):1655-1662. PubMed ID: 28544378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease.
    Goyal A; Verma A; Dubey N; Raghav J; Agrawal A
    J Food Biochem; 2022 Dec; 46(12):e14415. PubMed ID: 36106706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine.
    Jin S; Zhang L; Wang L
    Biomed Pharmacother; 2023 Sep; 165():115215. PubMed ID: 37494786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Derived Induced Pluripotent Stem Cell-Based Models in Parkinson's Disease for Drug Identification.
    Kouroupi G; Antoniou N; Prodromidou K; Taoufik E; Matsas R
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32993172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Human Pluripotent Stem Cells in Amyotrophic Lateral Sclerosis: From Biological Mechanism to Practical Implications.
    Ceccarelli L; Verriello L; Pauletto G; Valente M; Spadea L; Salati C; Zeppieri M; Ius T
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):114. PubMed ID: 38538275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.